Last edition
News about "KEYTRUDA QLEX"
Japan Approves Merck's Keytruda Qlex for Subcutaneous Use
Merck’s Keytruda Qlex receives MHLW approval in Japan for subcutaneous use across all locally approved Keytruda indications.
Keytruda Qlex | 22/09/2026 | By News Bureau | 101
US FDA Approves KEYTRUDA-WELIREG Combination for Adjuvant ccRCC
The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with WELIREG for the adjuvant treatment of certain patients with clear cell Renal Cell Carcinoma (ccRCC). The approval expands treatment options for kidney cancer patients at high risk of recurrence following surgery.
KEYTRUDA QLEX | 15/06/2026 | By News Bureau | 128
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy